Arteaga CL - Search Results

1

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.

Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Hanker AB, et al. Among authors: arteaga cl. Cancer Cell. 2021 Aug 9;39(8):1099-1114.e8. doi: 10.1016/j.ccell.2021.06.001. Epub 2021 Jun 24. Cancer Cell. 2021. PMID: 34171264 Free PMC article.

2

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Kurokawa H, et al. Among authors: arteaga cl. Cancer Res. 2000 Oct 15;60(20):5887-94. Cancer Res. 2000. PMID: 11059787

3

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. Lenferink AE, et al. Among authors: arteaga cl. Cancer Res. 2001 Sep 1;61(17):6583-91. Cancer Res. 2001. PMID: 11522658

4

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Moulder SL, et al. Among authors: arteaga cl. Cancer Res. 2001 Dec 15;61(24):8887-95. Cancer Res. 2001. PMID: 11751413

5

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Yakes FM, et al. Among authors: arteaga cl. Cancer Res. 2002 Jul 15;62(14):4132-41. Cancer Res. 2002. PMID: 12124352

6

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.

Arteaga CL. Arteaga CL. Breast Cancer Res. 2003;5(2):96-100. doi: 10.1186/bcr574. Epub 2003 Feb 3. Breast Cancer Res. 2003. PMID: 12631388 Free PMC article.

7

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

Arteaga CL, Baselga J. Arteaga CL, et al. Cancer Cell. 2004 Jun;5(6):525-31. doi: 10.1016/j.ccr.2004.05.028. Cancer Cell. 2004. PMID: 15193255 Free article.

8

EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.

Arteaga CL. Arteaga CL. Cancer Cell. 2006 Jun;9(6):421-3. doi: 10.1016/j.ccr.2006.05.014. Cancer Cell. 2006. PMID: 16766261 Free article. Review.

9

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. Wang SE, et al. Among authors: arteaga cl. Cancer Cell. 2006 Jul;10(1):25-38. doi: 10.1016/j.ccr.2006.05.023. Cancer Cell. 2006. PMID: 16843263 Free article.

10

HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta.

Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. Wang SE, et al. Among authors: arteaga cl. Cancer Res. 2006 Oct 1;66(19):9591-600. doi: 10.1158/0008-5472.CAN-06-2071. Cancer Res. 2006. PMID: 17018616

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

414 results

Search Page